Publications by authors named "M Hide"
Background: Type I allergy to sweat is involved in the pathogenesis of atopic dermatitis (AD) and cholinergic urticaria (CholU), with MGL_1304 from Malassezia globosa being the major causative antigen. Currently, no standard diagnostic test exists for sweat allergy that uses serum.
Methods: The ImmunoCAP (iCAP) system to measure antigen-specific IgE was developed using recombinant MGL_1304 (rMGL_1304).
Article Synopsis
- The 2024 clinical practice guidelines for atopic dermatitis (AD) focus on effectively managing this condition characterized by itchy, relapsing eczema.
- The primary goal of treatment is to quickly induce remission by reducing skin inflammation and itching, primarily using topical anti-inflammatory medications.
- The updated guidelines introduce five new treatments and emphasize the importance of evaluating research and weighing the pros and cons of various medical options to enhance patient outcomes.
Melioidosis is a neglected tropical disease caused by Burkholderia pseudomallei, endemic to Southeast Asia and Northern Australia. Despite its increasing global public health and clinical significance, the molecular epidemiology of melioidosis and genetic diversity of B. pseudomallei in Cambodia remains poorly understood.
View Article and Find Full Text PDFChronic spontaneous urticaria (CSU) is a typical example of an intractable skin disease with no clear cause and significantly affects daily life of patients. Because CSU is a human-specific disease and lacks proper animal model, there are many questions regarding its pathophysiological dynamics. On the other hand, most clinical symptoms of urticaria are notable as dynamic appearance of skin eruptions called wheals.
View Article and Find Full Text PDFArticle Synopsis
- Chronic spontaneous urticaria (CSU) shows a good response to omalizumab (OMA), but patients who don't respond well need a closer look at their long-term prognosis and treatment options.
- A study analyzed 48 patients who received three doses of OMA and tracked their progress over 12 months, finding that 28 had a good prognosis, while 20 had a less favorable outcome.
- Key factors linked to better outcomes included shorter CSU duration, presence of angioedema, low IgE levels pre-treatment, increased eosinophils after treatment, and higher urticaria control test scores; using immunosuppressants also predicted a better prognosis, while corticosteroids had a negative impact.